Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.

International journal of clinical and experimental pathology - 1 Jan 2015

Shao Xiying, Cai Jinwei, Zheng Yabing, Wang Jiwen, Feng Jianguo, Huang Yuan, Shi Lei, Chen Zhanhong, Guo Yong, Wang Xiaojia

Abstract excerpt

PURPOSE: The aim was to verify the potential association between CYP19A1 genetic polymorphisms and clinical outcome of hormone therapy in hormone receptor (HR)-positive early breast cancer. METHODS: Genotyping for CYP19A1 rs4646 (C/A) polymorphism was performed on 287 women with HR-positive early breast cancer. Associations were evaluated between CYP19A1 rs4646 genotypes and disease-free survival (DFS). RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Hormonal
Share to Aromatase
Share to Disease-Free Survival
Share to Neoplasms, Hormone-Dependent
Share to Patient Selection
Share to Postmenopause
Share to Premenopause
Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 26191232
PMCID: PMC4503103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.PMID 26191232Read ↗

The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer.Semantic proximity Read ↗

CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer.Semantic proximity Read ↗

Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.Semantic proximity Read ↗

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.Semantic proximity Read ↗

Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Semantic proximity Read ↗

The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.Semantic proximity Read ↗

The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.Semantic proximity Read ↗

Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.Semantic proximity Read ↗

Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.Semantic proximity Read ↗

Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.